MENLO PARK, Calif. , April 20, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ:PACB) will hold its quarterly conference call to discuss its First Quarter 2018 Financial Results on Wednesday, May 2, 2018 , at 4:30pm Eastern Time .

NIH-funded Program Focuses on Challenging Pediatric Cases; SMRT Sequencing Expected to Increase Solve Rate for Genetic Diagnosis MENLO PARK, Calif. , April 11, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq:PACB), the leader in long-read, high-resolution sequencing, today

MENLO PARK, Calif. , March 27, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq:PACB), the leader in long-read, high-resolution sequencing, today announced a purchase order for 10 PacBio ® Sequel ® Systems that are expected to be installed at Annoroad’s designated facility

MENLO PARK, Calif. , March 22, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq:PACB), the leader in long-read, high-resolution sequencing, today announced that Judge Leonard P. Stark of the U.S. District Court for the District of Delaware denied a motion to dismiss filed on

Clinical Research Effort Establishes New Quality Control Standards and Reveals Previously Undetected Risks for Gene Therapy Delivery MENLO PARK, Calif. , March 15, 2018 (GLOBE NEWSWIRE) -- A new publication in the journal of the American Society of Gene & Cell Therapy demonstrates the utility of

MENLO PARK, Calif. , March 13, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq:PACB), the leader in long-read, high-resolution sequencing, today announced that the U.S. Patent and Trademark Office (“USPTO”) has issued U.S. Patent No.

New Polymerase and Software Releases Improve Structural Variant Detection, Targeted Sequencing and RNA Sequencing Applications MENLO PARK, Calif. , March 07, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq:PACB), the leader in long-read, high-resolution sequencing, today

MENLO PARK, Calif. , Feb. 13, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ:PACB) (the "Company") today announced that it has priced its previously announced underwritten public offering of 12,500,000 shares of its common stock at a price to the public of $2.40 per

MENLO PARK, Calif. , Feb. 12, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ:PACB) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.  Pacific Biosciences also intends to grant the underwriters a 30-day option

Presentations will highlight importance of SMRT Sequencing for rare diseases, structural variation, and more